Compound class:
Synthetic organic
Comment: Compound A34 was reported as a selective FGFR4 inhibitor, with in vitro and in vivo anti-cancer activities [1]. In vitro A34 inhibits both the wild type FGFR4 and the FGFR4V550L mutant (IC50s 5.4 nM and 98.2 nM respectively).
![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
No information available. |
Summary of Clinical Use ![]() |
In vitro A34 inhibits the FGFR4V550L mutant more efficiently than the irreversible FGF4R inhibitor fisogatinib/BLU-554 (IC50s 89.2 nM and >1 μM respectively) [1]. A34 demonstrated anti-tumour activity in a murine Hep-3B hepatocellular carcinoma (HCC) xenograft model. Its kinase selectivity is very good, and its in vitro- and in vivo-determined PK parameters are favourable, with the risk of hERG channel-mediated cardiotoxicity assessed as being low. |